According to research, a boost in radiotherapy can help prevent the recurrence of an early form of breast cancer.


According to research, a boost in radiotherapy can help prevent the recurrence of an early form of breast cancer.

An additional radiation boost may lessen the likelihood that higher-risk DCIS would recur in the same breast, according to research partially supported by Breast Cancer Now.

In spite of the fact that women were more likely to remain cancer-free five years after having the additional therapy, the study also discovered that they were also more likely to develop negative side effects such as breast soreness and skin stiffening.

Breast Cancer Now has now given the researchers a fresh grant so that they can keep track of trial subjects and determine the long-term effects of the additional therapy.

Improving DCIS Treatment

Approximately 7,000 persons in the UK receive a ductal carcinoma in situ (DCIS) diagnosis each year. Breast cancer cells that have formed in the ducts of the breast but haven't yet spread to the surrounding tissue or other parts of the body are an early stage of the disease. According to estimates, half of DCIS cases will progress to aggressive breast cancer if managed.

Doctors typically advise breast-conserving surgery, which only removes a small portion of the breast that is damaged by DCIS. If there is a greater possibility that the DCIS will come back, radiation may occasionally be administered after this.

The University of Edinburgh, Western General Hospital, Edinburgh, University of Sheffield, Weston Park Hospital, Sheffield, and Royal Surrey County Hospital, Guildford all had teams working on the study under the direction of the Breast International Group. The researchers looked into whether giving radiotherapy an extra boost may assist in further preventing DCIS from recurring in the same region.

An added boost for radiation

Researchers examined the effectiveness of the additional dose at avoiding recurrence in 1,608 women with higher risk DCIS from 136 participant centres in 11 countries.

In comparison to 805 women who did not receive the additional boost of radiotherapy following surgery, they discovered that 803 women who did had a lower risk of cancer returning to the same location. Five years later, 97.1% of the women who received the additional care were cancer-free as opposed to 92.7% of the women who did not.

Boost radiation is regularly used to treat women with invasive breast cancer, but this is the first time we've been able to demonstrate that it's an effective treatment for women with higher risk DCIS, said Professor Ian Kunkler, Consultant in Clinical Oncology at the Edinburgh Cancer Centre, University of Edinburgh.

The women who received the additional radiation boost, nevertheless, were also more susceptible to adverse effects like breast soreness and skin stiffening.

Recognizing the long-term effects

Professor Ian Kunkler and his group at the University of Edinburgh have now received a fresh grant from Breast Cancer Now for £79,000 to support their work.

This will allow them to better understand some of the potential adverse effects that the UK trial participants may encounter as well as track if cancer recurrence continues to be reduced in the women who received the additional boost.

The Senior Research Communications Manager for Breast Cancer Now, Dr. Kotryna Temcinaite, added: "It's crucial that we create smarter, more efficient treatments for those with breast cancer, so it's incredibly encouraging that research we helped fund has shown that thousands of women who have higher risk of DCIS could use help from an extra dose of radiotherapy.

The increased funding for this research will allow us to better understand how the radiation boost can lower the risk of a cancer recurrence over a longer length of time. Additionally, it will assist determine which women will actually benefit from the additional care so that those who won't avoid needless additional radiotherapy that could lower their quality of life.

Previous Post Next Post